Mirae Asset Global ETFs Holdings
IKT icon

Mirae Asset Global ETFs Holdings’s Inhibikase Therapeutics IKT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.5K Buy
50,284
+21,409
+74% +$38K ﹤0.01% 2742
2025
Q4 		$59.2K Buy
28,875
+912
+3% +$1.45K ﹤0.01% 2890
2025
Q3 		$45.3K Sell
27,963
-5,060
-15% -$8.77K ﹤0.01% 2966
2025
Q2 		$64.4K Buy
+33,023
New +$64.7K ﹤0.01% 2812

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mirae Asset Global ETFs Holdings's IKT Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Inhibikase Therapeutics (IKT) stake by 74% in Q1 2026, buying an estimated $38K and bringing the position to 50,284 shares worth $84.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

Mirae Asset Global ETFs Holdings first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 50,284 shares of Inhibikase Therapeutics worth $84.5K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 21,409 Inhibikase Therapeutics shares in Q1 2026, an estimated $38K.
  • Inhibikase Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2742 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.